Details checkedClinical trial listing onlyCheckedregistry

Sisli Neural Therapy of Huneke Tinnitus Study

Also known as: Betahistine (Betaserc), Betahistine 24 mg bid (Betaserc), Neural Therapy of Huneke, NCT07334002

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Procedure/Rehab

Modality

Procedure/Rehab

Stage

Interventional/NA

Status

Active

Target Gene

—

Route / Mode

Periauricular and regional injection procedure; oral betahistine comparator

Confidence

84%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

Turkey

Population

adult, tinnitus

Trial IDs

Mechanism

Institution-led randomized controlled tinnitus study evaluating Neural Therapy of Huneke with local lidocaine injections against a betahistine active-comparator arm.

Indications

Tinnitus

Notes

Collapsed the generated betahistine/Betaserc comparator row into the actual Sisli randomized tinnitus study. ClinicalTrials.gov describes Neural Therapy of Huneke as the experimental procedure and betahistine as the active comparator, so betahistine should not appear as a standalone HearScape pipeline asset from this trial.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT07334002

Open

Key Events

2026-03-01

Registry lists estimated study start for Neural Therapy of Huneke tinnitus trial

Clinical Trials (1)

NCT07334002

Data Checks